Lobeglitazone API is a synthetic pharmaceutical active ingredient belonging to the thiazolidinedione (TZD) class of antidiabetic compounds. It is an insulin-sensitizing agent developed for the treatment of type 2 diabetes mellitus. Lobeglitazone acts primarily through activation of peroxisome proliferator-activated receptor gamma (PPAR-γ) and also demonstrates activity at PPAR-α. Activation of these nuclear receptors influences genes involved in glucose and lipid metabolism and improves insulin sensitivity.
Chemically, Lobeglitazone is identified as 5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione. The compound has the molecular formula C₂₄H₂₄N₄O₅S, molecular weight approximately 480.55 g/mol, and CAS No. 607723-33-1. PubChem, ChEBI and FDA substance records independently identify these core chemical characteristics.
Lobeglitazone is also known by the development code CKD-501 and is associated with the brand name Duvie. It was developed as an oral antidiabetic medicine and has been approved for treatment of type 2 diabetes in South Korea. Its pharmacological activity is based on improving insulin sensitivity through PPAR-mediated metabolic regulation.
The molecular structure of Lobeglitazone contains a thiazolidine-2,4-dione ring, a substituted phenoxy-pyrimidine moiety and an ether-linked aromatic system. These structural features contribute to its interaction with PPAR receptors and distinguish Lobeglitazone from other thiazolidinedione derivatives such as pioglitazone and rosiglitazone.
MEDIOCON INC supplies Lobeglitazone for pharmaceutical formulation development, analytical research, drug-development programs and applicable bulk API requirements, subject to product availability, applicable quality specifications, regulatory requirements and supporting documentation. MEDIOCON INC can support customers requiring Lobeglitazone for pharmaceutical R&D, analytical testing, formulation development and API sourcing, with the exact grade, assay, impurity profile, packaging and Certificate of Analysis to be confirmed for the specific batch.
It is important to distinguish Lobeglitazone from Lobeglitazone Sulfate in pharmaceutical databases. FDA substance records identify Lobeglitazone as the active moiety and Lobeglitazone Sulfate as a separate salt/parent relationship. Therefore, molecular weight, molecular formula and analytical specifications should not be transferred between the two forms without verification.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lobeglitazone API Manufacturer & Supplier in India | MEDIOCON INC (CAS 607723-33-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Lobeglitazone API Manufacturer & Supplier in India | MEDIOCON INC is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance